ZERBAXA 1.5g (ceftolozane 1g and tazobactam
0.5g) was approved by the European Commission in 2015 for use as indicated in adult patients with complicated urinary tract infections (cUTI), acute pyelonephritis, and complicated intra-abdominal infections (cIAI).
According to the company, ZERBAXA is an antibacterial combination product for intravenous infusion consisting of the cephalosporin antibacterial drug ceftolozane sulfate and the beta-lactamase inhibitor tazobactam
Although piperacillin sodium has been successfully used in avian medicine for many years because of its broad spectrum antibacterial properties, (2) piperacillin sodium/tazobactam sodium injectable (Zosyn, Wyeth, Philadelphia, PA, USA) was approved by the Food and Drug Administration in 1994 and is actually a superior product to piperacillin alone because of the addition of the [beta]-lactamase inhibitor tazobactam
. (3-6) This injectable antibacterial combination product is marketed for intravenous infusion in human patients.
Among them, predominant organisms were Gram-negative bacilli with Pseudomonas (18 isolates) being most common organism with the highest sensitivity to piperacillin + tazobactam
, imipenem and amikacin.
The second degree burns in a buffalo can be clinically treated and complete recovery was achieved with Ceftriaxone + Tazobactam
and Flunixin meglumine along with electrolyte, fluid therapy and topical application of antibiotic cream.
MIC of sulbactam, tazobactam
, meropenem, and colistin were determined by agar dilution method as per CLSI guidelines, The [MIC.sub.50] and [MIC.sub.90] were determined for all four anti biotics tested for MIC,
and Cefoperazone/Sulbactam are extensively used as beta-lactam/beta-lactamase inhibitor combination compounds for treatment of life threatening P.
This can be explained by the fact that AmpC [beta]-lactamase producers are more susceptible to tazobactam
as compared to clavulanic acid (4).
Tazocin is a combination of piperacillin sodium and the lactamase inhibitor tazobactam
Patients were randomized to intravenous treatment with either 1 g of ertapenem once daily, or 3.375 g of piperacillin plus tazobactam
every 6 hours.
Food and Drug Administration today approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam
) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.
inhibits the action of bacterial [beta]-lactatamases, especially those belonging to the SHV-1 and TEM groups.